RTTNews | Sep 30, 2021 07:58AM EDT

07:58 Thursday, September 30, 2021 (RTTNews.com) - Bausch + Lomb, the global eye health business of Bausch Health Companies Inc. (BHC, BHC.TO), and Novaliq GmbH reported statistically significant topline data from the second phase 3 trial evaluating the investigational drug NOV03 to treat the signs and symptoms of dry eye disease associated with Meibomian gland dysfunction. The company said the findings from this second phase 3 trial reinforces the results of the first phase 3 trial and further supports the efficacy and safety profile of NOV03.

The clinical development program for NOV03 is anticipated to conclude with an ongoing multi-center, open-label, single-arm, 12-month safety extension trial. The companies anticipate filing a New Drug Application to the FDA in 2022.

Read the original article on RTTNews ( https://www.rttnews.com/3229484/bausch-lomb-second-phase-3-trial-reaffirms-safety-efficacy-results-for-nov03.aspx)

For comments and feedback: contact editorial@rttnews.com

Copyright(c) 2021 RTTNews.com All Rights Reserved